Donald Mason - Waters
Donald Mason
Donald Mason is the Global Scientific Affairs Manager in the Health Sciences Diagnostics Business for Waters Corporation. For the past 15 years Don has played an active role in the clinical chemistry community developing the acceptance of liquid chromatographic and mass spectrometric techniques. Don has served on a number of scientific committees including Mass Spectrometry: Applications to the Clinical Lab and AACC’s Annual Meeting Organizing Committee (2015), editorial boards, and standards committees, including CLSI C62-A: Liquid Chromatography-Mass Spectrometry Methods; Approved Guideline.

Posts by author

The IVDR Cake. We’ve got a slice!

By April 14, 2022
European flags

Healthcare Providers and medical device manufacturers alike are working diligently to ensure that their services and products are compliant with these new regulations in the medical device industry in the European Union (EU).

Categories: Analytical Instrument Qualification
Tags: , , , , ,

Tune Into the Waters Renata Newborn Screening Podcast

By May 24, 2021
newborn screening

Learn more about the practice of newborn screening as we unravel the science behind it in our monthly Renata Newborn Screening Podcast series.

Categories: Clinical
Tags: , ,

National Newborn Screening Programs: An Overview of Challenges and Successes

By November 28, 2018

Don Mason reviews the state of newborn screening (NBS) programs around the world.

Categories: Clinical
Tags: , ,

The Historical Role of Mass Spectrometry in Newborn Screening

By September 24, 2018

Newborn screening for inherited metabolic disorders dates to the early 1960s when Dr. Robert Guthrie in Buffalo, New York developed the first screening test for phenylketonuria (or PKU), a metabolic disease in which patients can’t metabolize the amino acid phenylalanine.

Categories: Clinical
Tags: , ,

Laboratory Developed Tests: More Oversight, or More Vigilance and Reporting?

By December 1, 2015

U.S. FDA Prepares to Oversee LDTs Recently, the U.S. Food and Drug Administration’s Office of Public Health Strategy and Analysis issued an interesting (and much anticipated) report regarding Laboratory Developed Tests (LDTs). The Agency has… Read more >

Categories: Biomedical Research, Clinical